A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Exclusion Criteria

• •Participants must not have other diseases, conditions, or treatments that may confound interpretation of the effects of CC-97540 in SLE.
• •Uncontrolled or clinically significant cardiovascular conditions or CNS pathology participants must not have prior history of malignancies or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years, except for some non-invasive malignancies.
• •IOCBP who are pregnant, nursing, or breastfeeding, or who intend to become pregnant during participation in the study.
• •Participants must not have prior treatment with CAR T cell therapy, genetically modified T cell therapy, stem cell transplant or organ transplant.
• •Participants must not have received live vaccines within 6 weeks before LDC (lymphodepleting chemotherapy) administration.
• •Participant must not have inadequate organ function.